Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Platinum-based chemotherapy is now regarded a standard first-line treatment for patients with
advanced urothelial carcinoma (UC). However, patients who failed to response or experienced
progression after platinum-based chemotherapy have a grim prognosis and a standard salvage
treatment is not available.
UC is known to harbor multiple mutations. In the investigators' own high-throughput molecular
profiling study, the most commonly observed mutations included TP53, FGFR3(fibroblast growth
factor receptor 3 ) and HRAS. Since RAS signaling can be attenuated using selective farnesyl
transferase (FTase) inhibitors, tipifarnib, a highly potent and selective inhibitor of FTase,
was proposed to be an effective therapeutic approach in the treatment of UC.